Format

Send to

Choose Destination
Arch Bronconeumol. 2018 Dec 26. pii: S0300-2896(18)30446-0. doi: 10.1016/j.arbres.2018.11.002. [Epub ahead of print]

How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects.

[Article in English, Spanish]

Author information

1
Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona (UAB), Can Ruti Campus, Badalona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Electronic address: cvilaplana@gmail.com.
2
Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona (UAB), Can Ruti Campus, Badalona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Abstract

Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Guérin vaccine, which has been used since 1921 but exhibits only limited efficacy in the field. This effort has not, however, been entirely in vain as our understanding of TB vaccinology has been substantially expanded and there are currently 17 vaccine candidates in clinical development and several more in preclinical trials. This manuscript reviews the most important recent advances, concerns raised and future prospects in the TB vaccinology field.

KEYWORDS:

Bacille Calmette-Guérin; Bacilo Calmette-Guérin; Clinical trials; Ensayos clínicos; Tuberculosis; Vaccine; Vacuna

PMID:
30594319
DOI:
10.1016/j.arbres.2018.11.002
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center